Our in vitro and in vivo murine experiments showed that 111In-DOTA-dLVT selectively binds to OTR-positive cells and tumours, and is thus a potentially powerful reagent for the imaging and treatment of OTR-positive cancers. This evidence concerns the gene OXTR and neoplasm.